Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

Meanwhile, federal funding cuts and dismantled CDC HIV prevention programs could make it hard to reach the people most at risk—particularly low-income communities, women, and people of color.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Joint venture between GlaxoSmithKline and Pfizer in HIV illustrates opportunities to develop combination pills to challenge current market leaders. Nature Reviews Drug Discovery - Tapping into ...

HIV advocates hope lenacapavir, a long-acting, injectable HIV-prevention drug, could be a game changer in the fight against the virus. Nardus Engelbrecht / AP file Sept. 12, 2024, 9:43 AM EDT ...

"This really has the possibility of ending HIV transmission," said Greg Millett, public policy director at The Foundation for AIDS Research.

By Dennis Thompson HealthDay ReporterTUESDAY, May 13, 2025 (HealthDay News) — Drugs that battle HIV and hepatitis B might be able to help people avoid Alzheimer’s disease, a new study says.